CHMP Negative On PharmaMar's Aplidin In Multiple Myeloma

Clouds are gathering over Spanish firm PharmaMar as the EU's CHMP rejects its multiple myeloma therapy Aplidin. Its reasons are not yet forthcoming.

Storm clouds
Gathering Gloom For Aplidin • Source: Shutterstock

PharmaMar SA's second product, the marine-derived anticancer agent Aplidin (plitidepsin), was knocked back by the EU's CHMP at its meeting this week (Dec. 11-14) for the treatment of patients with relapsed multiple myeloma, in combination with dexamethasone.

The disappointment was not unexpected for the company after it received a preliminary feed-back (“trend vote”) from the EMA's scientific...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip